Trikafta (elexacaftor/tezacaftor/ivacaftor) improved lung function and reduced inflammation throughout the body over six months in patients with cystic…
Articles by Vanda Pinto, PhD
A single dose of 4D-710, an aerosol gene therapy candidate developed by 4D Molecular Therapeutics (4DMT) for adults with…
Treatment with Orkambi (lumacaftor/ivacaftor) for six months was found to improve exercise endurance in three adults with cystic…
For the second consecutive year, Owl Cyber Defense, a provider of network cybersecurity solutions, will be a presenting sponsor…
Supplemental oxygen lessened the abundance of some microbial species in sputum samples from people with cystic fibrosis (CF) while…
Children with cystic fibrosis (CF) whose intestinal microbe populations — or gut microbiome — were dominated by Bifidobacteria had…
Kaftrio (elexacaftor, tezacaftor, and ivacaftor) is safe and effective in children with cystic fibrosis (CF) ages 6 to…
A $2.7 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH),…
A fungus called Aspergillus fumigatus can significantly affect lung function and structure, as well as increase the number of pulmonary…
Home monitoring with a mobile phone-linked spirometry device may provide an effective way of detecting pulmonary exacerbations — episodes…